Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Johnson & Johnson’s pipeline IL-23 blocker, icotrokinra, has met its primary endpoint in a Phase IIb study in ulcerative colitis, meaning the drug’s efficacy and safety will now be explored in the ...

Skye Biosciences pipeline obesity drug, nimacimab, has failed to trigger significant weight loss as a monotherapy in a proof-of-concept Phase IIa trial. Image credit: Yellow_man / Shutterstock.com ...

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Comprehensive exploratory biomarker analyses were performed in the 3mg and 5mg multiple ascending dose cohorts. Credit: PeopleImages/Shutterstock.com. Ovid ...

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio prioritisation”.